LONDON, January 7, the global application software and services company, today announces that Philippine Farmers Bank has chosen Misys to strengthen its lending business and increase its ability to respond to and service its customers throughout the country.
Philippine Farmers Bank is a rural bank that provides retail banking services in the Philippines, including traditional deposit, loan products and cash management. Having established itself as the leading bank for both consumers and small and medium-sized businesses to have access to these services in one place, it is now focused on growing its business further and keeping ahead of the competition.
Philippines Farmers Bank selected Misys from among the several vendors offering a core banking solution. The bank was looking for a trusted partner with both the knowledge and the experience to help it to achieve its goals without impacting the high level of customer satisfaction the bank had built in its business.
"We turned to Misys because of its track record in the region and its ability to support banks growing their business," stated Ronaldo C. Alaya-ay, Manag
Wednesday, January 7, 2009
Ekahau Selected to Provide RTLS to University HealthSystem Consortium
RESTON, Virginia, January 7. Ekahau Inc., a leading provider of Wi-Fi-based Real Time Location Systems (RTLS), announced that after a competitive bid process it was awarded a multi-year agreement with University HealthSystem Consortium (UHC) to provide the Ekahau Real Time Location System (RTLS) solution to UHC member hospitals.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081014/324879-a )
This three-year agreement, with options to extend, positions Ekahau as the preferred provider of RTLS solutions to UHC's 294 member hospitals throughout the United States. Many of these institutions have Wi-Fi in place today making Ekahau's WI-Fi-based RTLS solution a logical choice for a cost-effective, quick deployment. Ekahau also has mutual certifications with all leading Wi-Fi infrastructure providers, further endorsing the benefits of Ekahau's location tracking solution to UHC and its member hospitals.
RTLS systems have become a mainstream technology in hospitals across the U.S. for tracking assets, inventory and patients and knowing the whereabouts of key staff members. Knowing the real-time whereabouts of these key assets has become mission critical to healthcare institutions, helping them reduce costs, improve workflow and increase the quality and timeliness of patient care.
"UHC is excited about entering into a new agreement with Ekahau because we believe they are one of the best RTLS system providers for our member hospitals," said Cindy White, UHC's vice president of operations. "We wanted a system that can cater to the unique tracking needs of each of our member hospitals and yet be simple and cost-effective to deploy."
Ekahau RTLS is a unique tracking system because it can locate objects using a hospital's existing Wi-Fi network, regardless of vendor or generation of the infrastructure. The Ekahau system is the only Wi-Fi-based system on the market that is capable of providing room-level accuracy using Wi-Fi without deploying proprietary chokepoints or readers, which can cause interference with medical equipment. Since Wi-Fi is typically deployed hospitalwide, Ekahau RTLS can extend location visibility across the entire campus or several campuses without any additional costs.
"We are very honored that UHC selected Ekahau as its RTLS partner of choice and to have the opportunity to serve the organization's member hospitals. The program we have put into place with UHC will allow UHC members to easily procure and roll out RTLS solutions to meet immediate needs and to have a platform for future growth and expandability as new requirements are put forth," said Tuomo Rutanen, Ekahau's vice president of business development. "During challenging economic times, like those we're experiencing today, RTLS systems can help businesses of all types save money. By leveraging existing Wi-Fi networks, Ekahau RTLS allows hospitals to better utilize their existing assets, resulting in lower capital spending, while driving significant operational efficiencies that reduce expenses and support improved patient care and safety initiatives."
Ekahau holds more than a dozen patents on its core location algorithms and processes that allow for the full modeling and analysis of RF data from the Wi-Fi network. Ekahau also offers the broadest set of Wi-Fi tags available to meet user- or application-specific needs. This powerful combination of software and hardware has been selected by thousands of customers worldwide to solve everyday business and operational problems.
About UHC
The University HealthSystem Consortium (UHC), formed in 1984, is an alliance of 103 academic medical centers and 191 of their affiliated hospitals representing approximately 90 percent of the nation's nonprofit academic medical centers. UHC offers its members specific programs and services to improve clinical, operational, and patient safety performance. The mission of UHC is to advance knowledge, foster collaboration, and promote change to help members succeed in their respective markets. For more information, visit http://www.uhc.edu.
About Ekahau Inc.
Ekahau Inc. is the industry leader in providing Wi-Fi-based RTLS solutions. Ekahau's customers, including several Fortune 500 companies worldwide, are realizing the benefits of Wi-Fi based location services and innovative Wi-Fi network planning and optimization tools. Ekahau's solutions are being used in more than 150 hospitals around the world, as well as by manufacturers, mining/oil/gas companies, government agencies and the military. Ekahau partners include wireless software developers, leading system integrators and international OEM partners, who develop and market wireless enterprise applications. Ekahau is a U.S. based corporation, with offices in Saratoga, Calif.; Reston, Va.; Helsinki, Finland; and Hong Kong, China. For more information about Ekahau, please visit at http://www.ekahau.com.
(c) Copyright 2009, Ekahau, Inc. All Rights Reserved.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081014/324879-a )
This three-year agreement, with options to extend, positions Ekahau as the preferred provider of RTLS solutions to UHC's 294 member hospitals throughout the United States. Many of these institutions have Wi-Fi in place today making Ekahau's WI-Fi-based RTLS solution a logical choice for a cost-effective, quick deployment. Ekahau also has mutual certifications with all leading Wi-Fi infrastructure providers, further endorsing the benefits of Ekahau's location tracking solution to UHC and its member hospitals.
RTLS systems have become a mainstream technology in hospitals across the U.S. for tracking assets, inventory and patients and knowing the whereabouts of key staff members. Knowing the real-time whereabouts of these key assets has become mission critical to healthcare institutions, helping them reduce costs, improve workflow and increase the quality and timeliness of patient care.
"UHC is excited about entering into a new agreement with Ekahau because we believe they are one of the best RTLS system providers for our member hospitals," said Cindy White, UHC's vice president of operations. "We wanted a system that can cater to the unique tracking needs of each of our member hospitals and yet be simple and cost-effective to deploy."
Ekahau RTLS is a unique tracking system because it can locate objects using a hospital's existing Wi-Fi network, regardless of vendor or generation of the infrastructure. The Ekahau system is the only Wi-Fi-based system on the market that is capable of providing room-level accuracy using Wi-Fi without deploying proprietary chokepoints or readers, which can cause interference with medical equipment. Since Wi-Fi is typically deployed hospitalwide, Ekahau RTLS can extend location visibility across the entire campus or several campuses without any additional costs.
"We are very honored that UHC selected Ekahau as its RTLS partner of choice and to have the opportunity to serve the organization's member hospitals. The program we have put into place with UHC will allow UHC members to easily procure and roll out RTLS solutions to meet immediate needs and to have a platform for future growth and expandability as new requirements are put forth," said Tuomo Rutanen, Ekahau's vice president of business development. "During challenging economic times, like those we're experiencing today, RTLS systems can help businesses of all types save money. By leveraging existing Wi-Fi networks, Ekahau RTLS allows hospitals to better utilize their existing assets, resulting in lower capital spending, while driving significant operational efficiencies that reduce expenses and support improved patient care and safety initiatives."
Ekahau holds more than a dozen patents on its core location algorithms and processes that allow for the full modeling and analysis of RF data from the Wi-Fi network. Ekahau also offers the broadest set of Wi-Fi tags available to meet user- or application-specific needs. This powerful combination of software and hardware has been selected by thousands of customers worldwide to solve everyday business and operational problems.
About UHC
The University HealthSystem Consortium (UHC), formed in 1984, is an alliance of 103 academic medical centers and 191 of their affiliated hospitals representing approximately 90 percent of the nation's nonprofit academic medical centers. UHC offers its members specific programs and services to improve clinical, operational, and patient safety performance. The mission of UHC is to advance knowledge, foster collaboration, and promote change to help members succeed in their respective markets. For more information, visit http://www.uhc.edu.
About Ekahau Inc.
Ekahau Inc. is the industry leader in providing Wi-Fi-based RTLS solutions. Ekahau's customers, including several Fortune 500 companies worldwide, are realizing the benefits of Wi-Fi based location services and innovative Wi-Fi network planning and optimization tools. Ekahau's solutions are being used in more than 150 hospitals around the world, as well as by manufacturers, mining/oil/gas companies, government agencies and the military. Ekahau partners include wireless software developers, leading system integrators and international OEM partners, who develop and market wireless enterprise applications. Ekahau is a U.S. based corporation, with offices in Saratoga, Calif.; Reston, Va.; Helsinki, Finland; and Hong Kong, China. For more information about Ekahau, please visit at http://www.ekahau.com.
(c) Copyright 2009, Ekahau, Inc. All Rights Reserved.
Research and Markets: Israel Ophthalmic Devices Investment Opportunities Report with Analysis and Forecasts to 2012
DUBLIN, Ireland Research and Markets (http://www.researchandmarkets.com/research/f27933/israel_ophthalmic) has announced the addition of Global Markets Direct's new report "Israel Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2012" to their offering.
This report is an essential source for in-depth information and data relating to the Israel ophthalmic devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the ophthalmic devices in Israel
Scope
* The report provides ophthalmic devices information broken down into detailed categories and segments in Israel.
* Total revenues, products sold, end users, and average pricing.
* Market shares of all the key competitors.
* Key pipeline products that are set to shape the market, broken down by sector.
* Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
* Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
* Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
* Key mergers and acquisitions, partnerships, private equity investments and IPOs.
* Customer, hospitals and physicians data.
Reasons to buy
* Gain a strong understanding of the ophthalmic devices market in Israel.
* Evaluate and compare the attractiveness of the market in the country.
* Identify growth segments and opportunities in each industry sector within the country.
* Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
* Analyze the competitiveness of the market in the country and identify hotspots.
* Develop strategies based on the latest product, brand, expansion and research and development news in the country.
* Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
* Identify and analyze the strengths and weaknesses of the industry incumbents in the country.
Key Topics Covered:
* Table of Contents
* Introduction
* Definitions of the Markets Covered in the Report
* Healthcare Sector Review
* Regulation System
* Pricing and Reimbursement
* Distribution Structure
* Ophthalmic Devices In Israel
* Cataract Surgery In Israel
* Refractive Surgery In Israel
* Vision Care In Israel
* Appendix
Companies Mentioned:
* Johnson & Johnson Vision Care, Inc.
* Bausch & Lomb Incorporated
* Essilor International
* Alcon, Inc.
* Advanced Medical Optics, Inc.
* CIBA Vision Corporation
* Acuity LTD.
* Medtechnica Ltd.
* NuLens Ltd.
* Shamir Optical Industry Ltd.
For more information visit http://www.researchandmarkets.com/research/f27933/israel_ophthalmic
Contact:
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
This report is an essential source for in-depth information and data relating to the Israel ophthalmic devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the ophthalmic devices in Israel
Scope
* The report provides ophthalmic devices information broken down into detailed categories and segments in Israel.
* Total revenues, products sold, end users, and average pricing.
* Market shares of all the key competitors.
* Key pipeline products that are set to shape the market, broken down by sector.
* Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
* Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
* Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
* Key mergers and acquisitions, partnerships, private equity investments and IPOs.
* Customer, hospitals and physicians data.
Reasons to buy
* Gain a strong understanding of the ophthalmic devices market in Israel.
* Evaluate and compare the attractiveness of the market in the country.
* Identify growth segments and opportunities in each industry sector within the country.
* Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
* Analyze the competitiveness of the market in the country and identify hotspots.
* Develop strategies based on the latest product, brand, expansion and research and development news in the country.
* Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
* Identify and analyze the strengths and weaknesses of the industry incumbents in the country.
Key Topics Covered:
* Table of Contents
* Introduction
* Definitions of the Markets Covered in the Report
* Healthcare Sector Review
* Regulation System
* Pricing and Reimbursement
* Distribution Structure
* Ophthalmic Devices In Israel
* Cataract Surgery In Israel
* Refractive Surgery In Israel
* Vision Care In Israel
* Appendix
Companies Mentioned:
* Johnson & Johnson Vision Care, Inc.
* Bausch & Lomb Incorporated
* Essilor International
* Alcon, Inc.
* Advanced Medical Optics, Inc.
* CIBA Vision Corporation
* Acuity LTD.
* Medtechnica Ltd.
* NuLens Ltd.
* Shamir Optical Industry Ltd.
For more information visit http://www.researchandmarkets.com/research/f27933/israel_ophthalmic
Contact:
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
SEATTLE, Jan. 7 announced today that it has received notification that the NASDAQ Listing Qualifications Panel has granted CTI's request to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market, which will be effective with the open of trading on Thursday, January 8, 2009. CTI's shares will continue to trade under the ticker symbol CTIC.
CTI's continued listing on The NASDAQ Capital Market is subject to CTI evidencing compliance with all applicable requirements for continued listing on The NASDAQ Capital Market, including the $35 million market value of listed securities requirement or its alternatives, as set forth in NASDAQ Marketplace Rule 4310(c)(3), by February 12, 2009. The Company expects to comply with all applicable requirements for continued listing on The NASDAQ Capital Market by February 12, 2009; however, there can be no assurance that it will be able to do so.
As disclosed on September 6 and October 10, 2008, CTI was previously notified by NASDAQ regarding its non-compliance with the $50 million market value of listed securities requirement for continued listing on The NASDAQ Global Market. In response, CTI appeared before the NASDAQ Listing Qualifications Panel at a hearing at which it requested the transfer of its listing to The NASDAQ Capital Market pursuant to its plan to evidence compliance with the $35 million market value of listed securities requirement for continued listing on that market.
The NASDAQ Capital Market is one of the three market tier designations for NASDAQ-listed stocks and operates in substantially the same manner as The NASDAQ Global Market. Securities listed on The NASDAQ Capital Market must satisfy all applicable qualification requirements for NASDAQ securities, and companies listed on The NASDAQ Capital Market must meet certain financial requirements and adhere to NASDAQ's corporate governance standards.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to achieve compliance with the NASDAQ Capital Market's continued listing requirements by February 12, including the market value of listed securities requirement, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's need to raise additional capital, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation, the potential failure of a product to prove safe and effective for treatment of a specific condition, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling the product(s). You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
http://www.CellTherapeutics.com/press_room
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T : 206.272.4347
F : 206.272.4434
E: invest@ctiseattle.com
http://www.CellTherapeutics.com/investors
CTI's continued listing on The NASDAQ Capital Market is subject to CTI evidencing compliance with all applicable requirements for continued listing on The NASDAQ Capital Market, including the $35 million market value of listed securities requirement or its alternatives, as set forth in NASDAQ Marketplace Rule 4310(c)(3), by February 12, 2009. The Company expects to comply with all applicable requirements for continued listing on The NASDAQ Capital Market by February 12, 2009; however, there can be no assurance that it will be able to do so.
As disclosed on September 6 and October 10, 2008, CTI was previously notified by NASDAQ regarding its non-compliance with the $50 million market value of listed securities requirement for continued listing on The NASDAQ Global Market. In response, CTI appeared before the NASDAQ Listing Qualifications Panel at a hearing at which it requested the transfer of its listing to The NASDAQ Capital Market pursuant to its plan to evidence compliance with the $35 million market value of listed securities requirement for continued listing on that market.
The NASDAQ Capital Market is one of the three market tier designations for NASDAQ-listed stocks and operates in substantially the same manner as The NASDAQ Global Market. Securities listed on The NASDAQ Capital Market must satisfy all applicable qualification requirements for NASDAQ securities, and companies listed on The NASDAQ Capital Market must meet certain financial requirements and adhere to NASDAQ's corporate governance standards.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to achieve compliance with the NASDAQ Capital Market's continued listing requirements by February 12, including the market value of listed securities requirement, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's need to raise additional capital, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation, the potential failure of a product to prove safe and effective for treatment of a specific condition, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling the product(s). You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
http://www.CellTherapeutics.com/press_room
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T : 206.272.4347
F : 206.272.4434
E: invest@ctiseattle.com
http://www.CellTherapeutics.com/investors
ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
Program Expands on Successful Results from prior U.S., U.K. and China Trials
SAN DIEGO, Jan. 7 Vital Therapies, Inc. (VTI), a development stage company targeting liver disease, announced patient enrollment has begun for a randomized, controlled, multi-center, Phase 2 clinical trial that will study the Extracorporeal Liver Assist Device (ELAD) as a treatment for patients with Acute Liver Failure (ALF) under three protocols. The study is open for enrollment at seven U.S. sites, which will be expanded to 15 sites in the U.S. and Europe during the first half of 2009. Six patients have already been enrolled in the first protocol and four patients have been treated under the emergency use Expanded Access regulations.
This trial expands on prior results from phase 1 and 2 U.S. and U.K. trials and a pivotal, randomized, controlled clinical trial at two sites in China during 2006/2007. In that study, 69 patients with hepatitis B or C who had suffered ALF were treated with either ELAD or standard therapy. Thirty day transplant free survival rates were statistically significant in the ELAD group vs. concurrent controls. A marketing application was submitted to China's State Food and Drug Administration (SFDA) in September 2007 and is under review.
ALF afflicts more than 30,000 U.S. patients each year including people with chronic liver disease like hepatitis, or without chronic disease, such as individuals whose livers were harmed by taking too much acetaminophen pain medicine.
For ALF patients, liver transplantation is the only therapy proven to impact survival. However, it has a cost exceeding $350,000 and there is a worldwide shortage of livers for transplant. ELAD was designed to address both problems since it may support regeneration of a patient's native liver, or maintain sufficient liver function until a transplant organ is available.
VTI Chairman and CEO Terry Winters, Ph.D., said, "With the continuing shortage of donor livers for transplantation and the large number of patients unlisted for transplant, patients are dying who do not have access to a donor liver or a living donor transplant. Our goal is to get ELAD to market as soon as possible so patients with ALF may have another treatment option."
VTI is currently enrolling patients in three separate protocols:
* Two are randomized, controlled studies of patients with ACLF (Acute-on-Chronic Liver Failure) or FHF (Fulminant Hepatic Failure). Continuous ELAD treatment is for a minimum of three and a maximum of 30 days.
* The third is an Expanded Access protocol with cost recovery allowing emergency treatment of patients who do not qualify for the first two protocols.
For more details on the protocols and study sites, please go to www.clinicaltrials.gov,
About ELAD
ELAD is a bedside system whose central component is four cartridges containing 440 grams of immortalized human liver cells and 32,000 hollow fibers. The patient's plasma flows inside of the hollow fibers to allow two-way transfer of metabolites. During ELAD therapy the cells metabolize toxins and synthesize proteins and other liver specific products essential for life. The ELAD cell cartridges are produced at VTI's GMP-compliant facility in San Diego, California.
About Vital Therapies Inc
Vital Therapies, Inc. (VTI) is based in San Diego, California, with a wholly owned subsidiary in Beijing, China. VTI is developing the first human liver cell-based Extracorporeal Liver Assist Device (ELAD). ELAD could provide support for patients with severe liver failure by processing toxins and synthesizing proteins and metabolites that are key products of normal human liver function. ELAD is in investigational clinical trials and VTI completed a pivotal trial and filed for market approval in China in September 2007.
ELAD is a trademark of Vital Therapies, Inc.
SAN DIEGO, Jan. 7 Vital Therapies, Inc. (VTI), a development stage company targeting liver disease, announced patient enrollment has begun for a randomized, controlled, multi-center, Phase 2 clinical trial that will study the Extracorporeal Liver Assist Device (ELAD) as a treatment for patients with Acute Liver Failure (ALF) under three protocols. The study is open for enrollment at seven U.S. sites, which will be expanded to 15 sites in the U.S. and Europe during the first half of 2009. Six patients have already been enrolled in the first protocol and four patients have been treated under the emergency use Expanded Access regulations.
This trial expands on prior results from phase 1 and 2 U.S. and U.K. trials and a pivotal, randomized, controlled clinical trial at two sites in China during 2006/2007. In that study, 69 patients with hepatitis B or C who had suffered ALF were treated with either ELAD or standard therapy. Thirty day transplant free survival rates were statistically significant in the ELAD group vs. concurrent controls. A marketing application was submitted to China's State Food and Drug Administration (SFDA) in September 2007 and is under review.
ALF afflicts more than 30,000 U.S. patients each year including people with chronic liver disease like hepatitis, or without chronic disease, such as individuals whose livers were harmed by taking too much acetaminophen pain medicine.
For ALF patients, liver transplantation is the only therapy proven to impact survival. However, it has a cost exceeding $350,000 and there is a worldwide shortage of livers for transplant. ELAD was designed to address both problems since it may support regeneration of a patient's native liver, or maintain sufficient liver function until a transplant organ is available.
VTI Chairman and CEO Terry Winters, Ph.D., said, "With the continuing shortage of donor livers for transplantation and the large number of patients unlisted for transplant, patients are dying who do not have access to a donor liver or a living donor transplant. Our goal is to get ELAD to market as soon as possible so patients with ALF may have another treatment option."
VTI is currently enrolling patients in three separate protocols:
* Two are randomized, controlled studies of patients with ACLF (Acute-on-Chronic Liver Failure) or FHF (Fulminant Hepatic Failure). Continuous ELAD treatment is for a minimum of three and a maximum of 30 days.
* The third is an Expanded Access protocol with cost recovery allowing emergency treatment of patients who do not qualify for the first two protocols.
For more details on the protocols and study sites, please go to www.clinicaltrials.gov,
About ELAD
ELAD is a bedside system whose central component is four cartridges containing 440 grams of immortalized human liver cells and 32,000 hollow fibers. The patient's plasma flows inside of the hollow fibers to allow two-way transfer of metabolites. During ELAD therapy the cells metabolize toxins and synthesize proteins and other liver specific products essential for life. The ELAD cell cartridges are produced at VTI's GMP-compliant facility in San Diego, California.
About Vital Therapies Inc
Vital Therapies, Inc. (VTI) is based in San Diego, California, with a wholly owned subsidiary in Beijing, China. VTI is developing the first human liver cell-based Extracorporeal Liver Assist Device (ELAD). ELAD could provide support for patients with severe liver failure by processing toxins and synthesizing proteins and metabolites that are key products of normal human liver function. ELAD is in investigational clinical trials and VTI completed a pivotal trial and filed for market approval in China in September 2007.
ELAD is a trademark of Vital Therapies, Inc.
Subscribe to:
Comments (Atom)